Agronomics Limited Announces Geltor, Inc Update
Agronomics (AGNMF) reports that portfolio company Geltor received a US FDA "No Questions" letter confirming GRAS status for PrimaColl®, the first biodesigned vegan collagen polypeptide cleared for food use.
PrimaColl® is commercially scaled, designed to mimic avian Type 21 collagen, and positioned for both ingestible and topical markets; topical availability is global. Agronomics has invested £7.2 million in Geltor to date, with the holding currently carried at approximately £237,617 (~0.16% of Agronomics NAV of £145.3m as of 30 June 2025).
Agronomics (AGNMF) riferisce che la società in portafoglio Geltor ha ricevuto una lettera US FDA "No Questions", che conferma lo status di GRAS per PrimaColl®, il primo polipeptide di collagene vegano biodesignato approvato per uso alimentare.
PrimaColl® è già prodotto su scala commerciale, progettato per imitare il collagene aviare Type 21, ed è destinato sia al mercato ingeribile che a quello topico; la disponibilità topica è globale. Agronomics ha investito finora £7,2 milioni in Geltor, con la partecipazione attualmente valutata a circa £237.617 (~0,16% NAV di Agronomics di £145,3m al 30 giugno 2025).
Agronomics (AGNMF) informa que la empresa de su cartera Geltor recibió una carta de la US FDA "No Questions", confirmando el estatus GRAS para PrimaColl®, el primer polipéptido de colágeno vegano diseñado biodesignado y aprobado para uso alimentario.
PrimaColl® está escalado comercialmente, diseñado para imitar el colágeno aviar Tipo 21, y está orientado a mercados tanto comestibles como tópicos; la disponibilidad tópica es global. Agronomics ha invertido 7,2 millones de libras en Geltor hasta la fecha, con la participación actualmente valorada en aproximadamente £237,617 (~0,16% NAV de Agronomics de £145,3m a 30 de junio de 2025).
Agronomics (AGNMF)는 포트폴리오 기업 Geltor가 미국 FDA로부터 "No Questions" 편지를 받아 GRAS 상태가 PrimaColl®에 대해 확인되었으며, 이것은 식품 사용이 허가된 최초의 바이오디자인 비건 콜라겐 폴리펩타이드입니다.
PrimaColl®은 상업적 규모로 생산되며, 조류 Type 21 콜라겐을 모방하도록 설계되었고, 섭취 가능 시장과 국소(피부) 시장 모두를 대상으로 합니다. 국소용은 전 세계적으로 이용 가능합니다. Agronomics는 지금까지 Geltor에 720만 파운드를 투자했으며, 보유 지분 가치는 현재 약 £237,617 (~Agronomics NAV £145.3m의 0.16% 2025년 6월 30일 기준).
Agronomics (AGNMF) annonce que la société de son portefeuille Geltor a reçu une lettre de la US FDA "No Questions", confirmant le statut GRAS pour PrimaColl®, le premier polypeptide de collagène végan biodesigné autorisé pour un usage alimentaire.
PrimaColl® est produit à l’échelle commerciale, conçu pour imiter le collagène aviaire Type 21, et positionné pour les marchés à la fois ingérables et topiques; la disponibilité topique est mondiale. Agronomics a investi 7,2 millions de livres dans Geltor à ce jour, la participation étant actuellement évaluée à environ £237,617 (~0,16% de la NAV d'Agronomics de £145,3m au 30 juin 2025).
Agronomics (AGNMF) berichtet, dass das Portfoliounternehmen Geltor ein US-FDA-"No Questions"-Schreiben erhalten hat, das den GRAS-Status für PrimaColl® bestätigt, das erste biodesignt veganes Kollagen-Polypeptid, das für den Lebensmittelgebrauch freigegeben ist.
PrimaColl® ist kommerziell skaliert, darauf ausgelegt, das avian Type 21 Kollagen zu imitieren, und richtet sich sowohl an den essbaren als auch an den topischen Markt; topische Verfügbarkeit ist global. Agronomics hat bisher 7,2 Mio. Pfund in Geltor investiert, wobei der Anteil derzeit auf ca. £237,617 (~0,16% des NAV von Agronomics von £145,3m zum 30. Juni 2025) beläuft.
Agronomics (AGNMF) يُبلغ عن أن شركة المحفظة Geltor تلقت رسالة من إدارة الغذاء والدواء الأمريكية "No Questions" تؤكد حالة GRAS لـPrimaColl®، أول سلسلة ببتيد كولاجين نباتية مُصممة حيويًا معتمدة للاستخدام الغذائي.
PrimaColl® مُقَدَّر على نطاق تجاري، مصمم ليقلد كولاجين من النوع 21 في الدواجن، وموجه إلى الأسواق القابلة للبلع والموضعية معاً؛ التوافر الموضعي عالمي. استثمرت Agronomics حتى الآن 7.2 مليون جنيه إسترليني في Geltor، وتُقدَّر الحصة حالياً بنحو £237,617 (~0.16% من صافي قيمة أصول Agronomics NAV البالغة £145.3m كما في 30 يونيو 2025).
Agronomics (AGNMF) 报告，其投资组合公司 Geltor 收到美国 FDA 的“No Questions”信函，确认 PrimaColl® 的 GRAS 状态，这是首个生物设计的纯素胶原蛋白肽，已获准用于食品。
PrimaColl® 已实现商业化规模，设计用于模拟鸟类 Type 21 胶原蛋白，面向可口服和局部用市场；局部用在全球范围内可用。至今，Agronomics 已在 Geltor 投资 720 万英镑，持股当前估值约为 £237,617（约占 Agronomics NAV £145.3m 的 0.16%，基于 2025 年 6 月 30 日的数据）。
- FDA GRAS clearance for PrimaColl® (no questions letter)
- Commercial-scale production achieved in 2022
- PrimaColl® cleared for both ingestible and topical applications
- Certified Vegan, Halal, Kosher, and non-GMO
- Agronomics invested £7.2m but holding carried at £237,617
- Holding equals ~0.16% of NAV (£145.3m as of 30 June 2025)
DOUGLAS, ISLE OF MAN, GB / ACCESS Newswire / October 21, 2025 / Agronomics (LSE:ANIC), the leading listed company in the field of clean food, is pleased to announce that its portfolio company Geltor, Inc. ("Geltor") has received a 'No Questions' Letter from the US Food and Drug Administration ("FDA"), confirming the Generally Recognized As Safe ("GRAS") status of its PrimaColl® ingredient - the world's first biodesigned vegan collagen polypeptide.
Geltor is a California-based biodesign company producing sustainable, animal-free proteins through precision fermentation. This regulatory milestone enables the company to advance its commercial expansion into global nutrition and wellness markets.
Jim Mellon, Executive Chair of Agronomics, commented:
"This FDA recognition marks a pivotal moment for both Geltor and the broader field of sustainable protein innovation. Collagen is a multi-billion-dollar global market still dominated by animal-derived products. As demand continues to rise, PrimaColl represents a meaningful step toward producing this essential ingredient without dependence on industrial agriculture, offering a more ethical, traceable and environmentally responsible alternative. Agronomics see these kinds of biotechnological advances as key to building a more secure and resilient global food system, fully aligned with our mission to back companies driving the transition to clean, sustainable food."
Agronomics first invested in Geltor on 21 February 2022, and to date has invested a total of
The full announcement is set out below, with no material changes:
Geltor's PrimaColl® Becomes First Biodesigned Collagen Polypeptide Cleared for Food & Beauty, Redefining Longevity Inside and Out
FDA GRAS clearance (no questions letter) and global topical availability position PrimaColl® as the first commercially viable biotech-derived collagen alternative spanning beauty, wellness, and nutrition.
Geltor, the leader in biodesigned proteins for beauty and wellness, today announced the commercial arrival of PrimaColl®, the first and only biodesigned collagen polypeptide available for both ingestible and topical applications. As the first collagen to be added to the FDA inventory since 1999, its FDA "Generally Recognized as Safe" (GRAS) clearance in the U.S. and worldwide topical availability, PrimaColl® represents a major milestone for the collagen category and a turning point for science-backed longevity ingredients.
PrimaColl® is designed to mimic an amino acid sequence of avian Type 21 collagen, making it ideal for food and nutrition applications. First introduced in 2021 and successfully scaled to full commercial production in 2022, PrimaColl® has already proven the industrial viability of biodesigned proteins. Now, with FDA clearance and large-scale economics, PrimaColl® delivers a single collagen solution across two massive markets - food & beverage and beauty & personal care.
Why PrimaColl® Matters Now
InsightAce Analytic values the beauty ingestibles market in 2024 at
Consumers are increasingly seeking proactive, science-backed solutions that support living better for longer. Collagen sits at the center of this movement. PrimaColl® offers brands and consumers a future-proof alternative, with precision design, high purity, reliable, and consistent supply.
Ingestible: Clinical studies have shown that daily consumption improves skin elasticity, firmness, and moisturization, while also reducing wrinkle depth.
Topical: Shown to promote collagen and support skin renewal. For hair, it enhances hair manageability via film-forming properties that reduce frizz and resist humidity. Available globally for beauty and personal care applications.
Inclusive & Sustainable: Produced through precision fermentation, PrimaColl® is
100% animal-free, certified Vegan, Halal, Kosher, and non-GMO.
"PrimaColl® has received the FDA's 'no questions' response to its GRAS notification, making it the first biotech collagen to achieve this milestone. With its proven scalability and ability to serve both food & beverage, as well as beauty & personal care applications, it represents a pivotal step forward at the intersection of beauty, wellness, and longevity. I am excited to see the transformative products our partners will create with it," said Alex Lorestani, CEO and Co-founder of Geltor.
Availability
PrimaColl® is now open for sampling and formulation. Brands and formulators can experience it firsthand at California Suppliers' Day, October 29-30, Booth #479, schedule a meeting at sales@geltor.com, or request samples at www.geltor.com/primacoll.
Notes to Editors
About Geltor
Geltor, headquartered in San Leandro, CA, is the category leader in biodesigned proteins, creating sustainable, high-performance ingredients for the world's most innovative beauty, food, and wellness brands. By harnessing the power of precision fermentation, Geltor enables a new era of clean, functional, and scalable proteins that meet the evolving needs of consumers worldwide.
Its PrimaColl® collagen, granted FDA GRAS clearance and available worldwide, is the first collagen added to the FDA inventory since 1999, marking a breakthrough in science-backed longevity ingredients. Visit us at www.geltor.com
About Agronomics
Agronomics is a leading London-listed company focused on investment opportunities within the field of cellular agriculture. The Company has established a portfolio of over 20 companies developing technologies that produce food and materials, historically derived from animals, offering solutions for improved sustainability, human health, and food security.
A full list of Agronomics' portfolio companies is available at https://agronomics.im.
For further information, please contact:
Agronomics Limited | Beaumont Cornish Limited | Canaccord Genuity Limited | Cavendish Capital Markets Limited | Peterhouse Capital Limited | 33Seconds Limited |
The Company | Nomad | Joint Broker | Joint Broker | Joint Broker | Public Relations |
Jim Mellon Denham Eke | Roland Cornish James Biddle | Andrew Potts Harry Pardoe | Giles Balleny Michael Johnson | Lucy Williams Charles Goodfellow | Jack Ferris Amber Carr |
+44 (0) 1624 639396 info@agronomics.im | +44 (0) 207 628 3396 | +44 (0) 207 523 8000 | +44 (0) 207 397 8900 | +44 (0) 207 469 0936 |
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media-only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Agronomics Limited
View the original press release on ACCESS Newswire
FAQ
What did Agronomics announce about Geltor's PrimaColl® on October 21, 2025 (AGNMF)?
What does FDA GRAS clearance mean for Geltor's PrimaColl® and AGNMF investors?
Is PrimaColl® available for beauty and nutrition applications now?
How much has Agronomics invested in Geltor and how is the holding carried?
How material is the Geltor holding to Agronomics' portfolio (AGNMF)?
